Logo

Roche Taps Compugen to Seek Non-SNP Markers for Drug Response

Dec 21, 2007
NEW YORK (GenomeWeb News) – Compugen and Roche have agreed to collaborate in an effort to search for biomarkers that could help predict patient responses to drugs aimed at treating rheumatoid arthritis, Compugen said Thursday.
 
Compugen will use its GeneVa database, which holds around 200,000 non-SNP genetic variations, to investigate DNA samples for markers that could predict response or non-response to selected drugs Roche intends to develop.
 
GeneVa includes algorithms and other computational biology tools to find variations that are associated with specific phenotypes that may be linked to particular drug responses.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.